cytidine has been researched along with pyrazines in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 11 (73.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hilgenfeld, R; Jochmans, D; Ma, Q; Nascimento, MS; Neyts, J; Rocha-Pereira, J | 1 |
| Behera, I; Beigelman, L; Deval, J; Dyatkina, N; Jin, Z; Kao, CC; Lin, X; Rajwanshi, VK; Shaw, K; Symons, J; Tan, H; Tucker, K; Wang, G | 1 |
| Neyts, J; Rocha-Pereira, J; Van Dycke, J | 1 |
| Behera, I; Beigelman, L; Chaudhuri, S; Deval, J; Dyatkina, N; Jekle, A; Jin, Z; Kinkade, A; Rajwanshi, VK; Smith, DB; Symons, JA; Tucker, K; Wang, G | 1 |
| Plemper, RK; Toots, M | 1 |
| Barfuss, P; Demirbag, S; Khan, KS; Le, TK; Ng, WL; Paris, C; Robson, F; Rocchi, P | 1 |
| Govil, A; Luckett, K; Miller-Handley, H | 1 |
| Saladini, F; Vicenti, I; Zazzi, M | 1 |
| Abdelnabi, R; Augustijns, P; Breuer, J; Chatterjee, AK; Coelmont, L; Dallmeier, K; De Jonghe, S; Do, TND; Foo, CS; Heylen, E; Jochmans, D; Kaptein, SJF; Langendries, L; Leyssen, P; Mols, R; Neyts, J; Pang, J; Vangeel, L; Vergote, V; Weynand, B; Williams, R; Zhang, X | 1 |
| Tsanni, A | 1 |
| Eloy, P; Guedj, J; Le Grand, R; Malvy, D | 1 |
| Hughes, C; Lewis, P; Warren, S; Waters, MD; Zhang, F | 1 |
| Al-Harrasi, A; El Deeb, S; Ibrahim, AE; Sayed, RA; Sharaf, YA | 1 |
| Deeb, SE; Ibrahim, AE; Salman, BI; Saraya, RE | 1 |
| Kulkarni, P; Padmanabhan, S | 1 |
5 review(s) available for cytidine and pyrazines
| Article | Year |
|---|---|
Next-generation direct-acting influenza therapeutics.
Topics: Amides; Antibodies, Neutralizing; Antiviral Agents; Cytidine; Dibenzothiepins; Drug Resistance, Viral; Humans; Hydroxylamines; Influenza, Human; Morpholines; Neuraminidase; Oxazines; Pyrazines; Pyridines; Pyridones; Ribonucleosides; RNA-Dependent RNA Polymerase; Thiepins; Triazines; Virus Replication | 2020 |
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytidine; Genome, Viral; Humans; Hydroxylamines; Molecular Targeted Therapy; Mutation; Pandemics; Pneumonia, Viral; Pyrazines; Ribonucleosides; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Transcription, Genetic; Viral Nonstructural Proteins; Virus Replication | 2020 |
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Creatinine; Cytidine; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Hydroxychloroquine; Hydroxylamines; Immunization, Passive; Interferons; Janus Kinase Inhibitors; Lopinavir; Pyrazines; Renal Elimination; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Development; Drug Repositioning; Humans; Hydroxylamines; Pyrazines; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2021 |
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Deoxyuridine; DNA Damage; Genome, Human; Humans; Hydroxylamines; Mutagenesis; Nucleosides; Pyrazines; Ribavirin; SARS-CoV-2 | 2022 |
10 other study(ies) available for cytidine and pyrazines
| Article | Year |
|---|---|
The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon.
Topics: Amides; Antiviral Agents; Cell Line; Cysteine Endopeptidases; Cytidine; Drug Combinations; Drug Synergism; Hepatocytes; Humans; Isoxazoles; Molecular Docking Simulation; Norwalk virus; Papain; Phenylalanine; Pyrazines; Pyrrolidinones; Replicon; RNA-Dependent RNA Polymerase; Valine; Viral Proteins; Virus Replication | 2014 |
Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.
Topics: Amides; Animals; Antiviral Agents; Cell Line, Tumor; Cytidine; DNA-Directed RNA Polymerases; Escherichia coli; Gene Expression Regulation, Viral; Hepatocytes; Host Specificity; Humans; Kinetics; Mice; Norovirus; Pyrazines; Recombinant Proteins; Ribonucleotides; Transcription, Genetic; Viral Proteins; Virus Replication | 2015 |
Treatment with a Nucleoside Polymerase Inhibitor Reduces Shedding of Murine Norovirus in Stool to Undetectable Levels without Emergence of Drug-Resistant Variants.
Topics: Amides; Animals; Caliciviridae Infections; Cytidine; Disease Models, Animal; Feces; Gastroenteritis; Mice; Mice, Knockout; Norovirus; Pyrazines; Receptors, Interferon; Transplant Recipients; Virus Shedding | 2015 |
Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs.
Topics: Adenosine; Amides; Antiviral Agents; Cell Line; Cytidine; DNA-Directed RNA Polymerases; Guanosine Monophosphate; Humans; Inhibitory Concentration 50; Mitochondria; Mitochondrial Proteins; Nucleosides; Prodrugs; Protein Biosynthesis; Pyrazines; Ribonucleosides; RNA; RNA, Mitochondrial; Sofosbuvir; Structure-Activity Relationship; Transcription Initiation Site; Transcription, Genetic | 2017 |
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
Topics: Amides; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Disease Models, Animal; Drug Therapy, Combination; Female; Hydroxylamines; Lung; Mesocricetus; Pyrazines; RNA, Viral; Treatment Outcome; Viral Load | 2021 |
African scientists race to test COVID drugs - but face major hurdles.
Topics: Africa; Amides; Amodiaquine; Artesunate; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Drug Therapy, Combination; Humans; Hydroxylamines; Imidazoles; Ivermectin; Naphthyridines; Nitro Compounds; Pregnenediones; Pyrazines; Pyrrolidines; Ritonavir; Sample Size; Thiazoles; Valine; World Health Organization | 2021 |
Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
Topics: Amides; Animals; Antiviral Agents; COVID-19 Drug Treatment; Cricetinae; Cytidine; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxylamines; Pyrazines; SARS-CoV-2 | 2021 |
Two Green Micellar HPLC and Mathematically Assisted UV Spectroscopic Methods for the Simultaneous Determination of Molnupiravir and Favipiravir as a Novel Combined COVID-19 Antiviral Regimen.
Topics: Amides; Antiviral Agents; Chromatography, High Pressure Liquid; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Micelles; Pandemics; Pyrazines; Reproducibility of Results; SARS-CoV-2; Spectrophotometry, Ultraviolet | 2022 |
Highly sensitive high-performance thin-layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations.
Topics: Amides; Antiviral Agents; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; COVID-19 Drug Treatment; Cytidine; Drug Compounding; Humans; Hydroxylamines; Pyrazines; Reproducibility of Results; Ritonavir; SARS-CoV-2 | 2022 |
A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.
Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Deoxyglucose; Hexokinase; Humans; Hydroxylamines; Molecular Docking Simulation; Pyrazines; SARS-CoV-2 | 2022 |